Exelixis, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0IJO.L | HCM | 688266.SS | RCUS | 2410.HK | 300558.SZ | |
|---|---|---|---|---|---|---|
| Market cap | — | 2.42B | 24.15B | 2.43B | 1.21B | 20.76B |
| P/E (TTM) | 77.9 | 139.2 | 42.6 | — | — | 77.9 |
| Forward P/E | — | 53.7 | 73.0 | -6.2 | -6.1 | 29.2 |
| Price/book | 9.6 | 1.9 | 14.1 | 3.8 | 4.0 | 3.2 |
| Dividend yield | — | — | — | — | — | 0.31% |
| 1-year change | +78.09% | −9.90% | −10.38% | −1.28% | −80.24% | −12.57% |
| Today | −1.09% | +6.42% | +0.12% | +2.12% | +9.61% | +1.62% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0IJO.L news ›Exelixis Accuses Handa of Infringing New Cancer Treatment Patent
Bloomberg Law News Exelixis Inc. sued Handa Pharmaceuticals Inc. Tuesday to stop its plans to sell a drug that allegedly infringes Exelixis’ patent protecting its cancer medication Cabometyx, issued the same day. Handa’s Omcazio treatm
Investment Analysts’ Recent Ratings Updates for Exelixis (EXEL)
Posted by Danessa Lincoln on Nov 3rd, 2026 Exelixis (NASDAQ: EXEL) has recently received a number of price target changes and ratings updates: Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and…
Exelixis Rises with Earnings on Tap
Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017. It’s no wonder EXEL shares are up 42% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the…
What Was Exelixis Telling You Before Its Stock Ran?
Shares of Exelixis (EXEL) returned 76.0% between October 29, 2025, and October 30, 2026, compared with 11.3% for the S&P 500. During that year, the FDA accepted the company’s application for its experimental cancer drug zanzalintinib.…
Exelixis (NASDAQ:EXEL) Given New $78.00 Price Target at HC Wainwright
Posted by Mitch Edgeman on Nov 2nd, 2026 Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective lifted by analysts at HC Wainwright from $56.00 to $78.00 in a research report issued to clients and investors on Monday, Benzinga…
Exelixis outlines March 3, 2027 PDUFA for zanza while advancing Wave 2 pivotal plans
Exelixis Q3 2026 earnings: CABOMETYX growth, zanzalintinib pipeline milestones, and key 2027 catalysts. Earnings Call Insights: Exelixis (EXEL) Q3 2026 - Michael Morrissey framed zanzalintinib as the next growth driver, saying,…
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million – – GAAP Diluted EPS of $0.85, Non-GAAP Diluted EPS of $0.94 – – Conference Call and Webcast Today at 5:00 PM ET – ALAMEDA,…
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, TD Cowen Analyst Says
Posted by Tristan Rich on Oct 30th, 2026 Exelixis (NASDAQ:EXEL – Get Free Report) had its target price boosted by equities researchers at TD Cowen from $55.00 to $76.00 in a report issued on Friday, Benzinga reports. The firm currently has…
Exelixis Non-GAAP EPS of $0.94 beats by $0.04, revenue of $658.7M beats by $10.19M
Exelixis tops Q3 estimates with $0.94 EPS and $658.7M revenue, while lowering its tax rate outlook. - Exelixis press release (EXEL): Q3 Non-GAAP EPS of $0.94 beats by $0.04. - Revenue of $658.7M (+10.2% Y/Y) beats by $10.19M. (provided on…
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
It has also continued to grind out new indications, including as a combination therapy. Exelixis' financial results have been strong thanks to this drug. In the second quarter, the company's revenue increased by 10.6% year over year to…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com5
- themarketsdaily.com5
- marketscreener.com2
- trefis.com2
- biospace.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 22 articles, not a forecast.